Sex-specific differences in drug treatment;Geschlechtsspezifische aspekte in der pharmakotherapie - Was ist gesichert?

Zeitschrift fur Allgemeinmedizin

Volumn 82, Issue 9, 2006, Pages 380-384

  Thürmann, Petra A ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Adverse drug reaction; Clinical trials; Drug effects; Pharmacokinetics; Sex specific

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; COPING BEHAVIOR; DRUG METABOLISM; GENERAL PRACTITIONER; HEART INFARCTION; HUMAN; PATHOPHYSIOLOGY; PRESCRIPTION; QT PROLONGATION; REVIEW; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33750595553     PISSN: 09376801     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-942089     Document Type: Review

References (28)

1. Martin R, Biswas PN, Freemantle SN, et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998;46:505-511
2. Schröder H, Selke W. Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe U, Paffrath D (Hrsg). Arzneiverordnungsreport 2000. Springer, Berlin 2000; 770-783
3. Thürmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36: 586-590
4. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41: 329-342
5. Thürmann PA. Geschlechtsspezifische Unterschiede bei der Pharmakokinetik und -dynamik von Arzneimitteln. Bundesgesundheitsblatt Gesundheitsforsch Gesundheitsschutz 2005; 48: 536-540
6. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193-209
7. Spranger M, Aspey BS, Harrison MJG. Sex difference in antithrombotic effect of aspirin. Stroke 1989; 20: 34-37
8. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304
9. Berger J, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA 2006; 295: 306-313
10. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004; 291: 2243-2252
11. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-1411
12. Blaustein MP, Robinson SW, Gottlieb SS, et al. Sex, digitalis and the sodium pump. Mol Interv 2003; 3: 68-72
13. Luchner A, Bröckel U, Muscholl M, et al. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res 2002; 53: 720-727
14. Adams KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group Trial. A retrospective analysis. J Am Coll Cardiol 2005; 46: 497-504
15. Hippius M, Humaid B, Sicker T, et al. Adverse drug reaction monitoring - digitoxin overdosing in very old age. Int J Clin Pharm Ther 2001; 39: 336-343
16. Thürmann PA, Szymanski J, Valentin S, et al, Hasford J for the German Pharmacovigilance Study Group. Drug-related hospital admissions: a gender- and age-specific analysis. Int J Clin Pharmacol Ther 2003; 41: 555
17. Anastos K, Charney P, Charon RA, et al. Hypertension in women: what is really known? The women's caucus, working group on women's health of the Society of General Internal Medicine. Ann Intern Med 1991; 115: 287-293
18. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001; 286: 708-713
19. Vidaver RM, Lafleur B, Tong C, et al. Women subjects in NIH-funded clinical research literature: lack of progress in both representation and analysis by sex. J Womens Health Gend Based Med 2000; 9: 495-504
20. Wuttke H, Rau T, Heide R, et al. In-creased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429-437
21. Glaeske G, Janhsen K. GEK-Arzneimittel-Report 2004. Schriftenreihe zur Gesundheitsanalyse 2004; 29
22. Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004; 60: 135-142
23. Finn VW. Sex and gender factors in medical studies. Implications for health and clinical practice. JAMA 2003; 289: 397-400
24. Kornstein SG, Sloan DM, Thase ME. Gender-differences in depression and treatment response. Psychopharmacol Bull 2002; 36: 99-112
25. Hildebrandt MG, Steyerberg EW, Stage KB, et al. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 2003; 160: 1643-1650
26. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157: 1445-1452
27. Seeman MV. Gender differences in prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161: 1324-1333
28. Fleisch J, Fleisch MC, Thurmann PA. Women in early-phase clinical drug trials: have things changed over the past 20 years? Clin Pharmacol Ther 2005; 78: 445-452